Humbert M, McLaughlin V, Gibbs JSR, et al. - Researchers undertook this 24-week multicenter trial to test sotatercept (a novel fusion protein) as a treatment option for pulmonary arterial hypertension. Participants were 106 adults who were taking background therapy for pulmonary arterial hypertension. These were randomized to receive subcutaneous sotatercept at a dose of 0.3 mg per kilogram of body weight every 3 weeks, 0.7 mg per kilogram every 3 weeks, or placebo. Findings demonstrated that a decrease in pulmonary vascular resistance was conferred by sotatercept in patients receiving background therapy for pulmonary arterial hypertension. Sotatercept was also linked to a decrease in N-terminal pro–B-type natriuretic peptide levels.